GlobeNewsWire · ZYME · October 23, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Get the app for more

Explore stock news, insights and company research.